Hasta Alanına Git

Haritası
  1. Coates TD and Wood JC, How we manage iron overload in sickle cell patients. Br J Haematol. 2017 June; 177(5):703-716
  2. Hider RC and Hoffbrand AV, The Role of Deferiprone in Iron Chelation. N Engl J Med 2018; 379:2140-50
  3. Ballas SK et al. The effect of iron chelation therapy on overall survival in sickle cell disease and b-thalassemia: A systematic review. Am J Hematol. 2018; 93:943–952
  4. Beris P, Transfusion and Iron Overload: Where Are the Risks? HAEMA 2019; 10(1):29-38
  5. Children’s Hospital & Research Center Oakland. Standards of Care Guidelines for Thalassemia 2012
  6. Coates TD. Physiology and pathophysiology of iron in hemoglobin-associated diseases. Free Radical Biology and Medicine 72(2014)23–40
  7. Borgna-Pignatti C et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. haematologica 2004;89:1187-1193
  8. Fung EB et al. Morbidity and Mortality in Chronically Transfused Subjects With Thalassemia and Sickle Cell Disease: A Report From the Multi-Center Study of Iron Overload. American Journal of Hematology (2007) 82:255–265
  9. Coates TD et al. Management of iron overload in hemoglobinopathies: what is the appropriate target iron level? Ann. N.Y. Acad. Sci. 1368 (2016) 95–106
  10. Brittenham GM, Iron-Chelating Therapy for Transfusional Iron Overload. N Engl J Med. 2011 January 13; 364(2): 146–156
  11. Chou ST, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood advances 28 January 2020; Volume 4, Number 2
  12. Sundaram N, et al. Biomarkers for early detection of sickle nephropathy. Am J Hematol. 2011 July ; 86(7): 559–566
  13. Pennell DJ, et al. On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure. Journal of Cardiovascular Magnetic Resonance 2011, 13:45
  14. Sheth S, Monitoring of Iron Overload in Transfusion-Dependent Thalassemia (TDT). NewYork-Presbyterian Hospital/Weill Cornell Medical Center
  15. Abetz L, et al. The impact of iron overload and its treatment on quality of life: results from a literature review. Health and Quality of Life Outcomes 2006, 4:73
  16. Cappellini MD, et al. 2021 Guidelines for the Management of Transfusion Dependent Thalassaemia. 4th Edition. 2021, Thalassaemia International Federation
  17. Brissot P, et al. Laboratory medicine and iron overload: diagnostic and therapeutic aspects. J Lab Precis Med 2020;5:25
  18. Tsai TA, et al. Higher Hospitalization Rate for Lower Airway Infection in Transfusion-Naïve Thalassemia Children. Children. Front. Pediatr. 2020, 8:574014
  19. Booth C, et al. Infection in sickle cell disease: A review. International Journal of Infectious Diseases (2010) 14, e2—e12
  20. Standards for the Clinical Care of Children and Adults with Thalassaemia in the UK. United Kingdom Thalassaemia Society 2016 3rd Edition
  21. Pennell DJ, et al. Cardiovascular Function and Treatment in β-Thalassemia Major. A Consensus Statement From the American Heart Association. Circulation. 2013;128:281-308
  22. Sirlin CB and. Reeder SB. Magnetic Resonance Imaging Quantification of Liver Iron. Magn Reson Imaging Clin N Am. 2010 August ; 18(3): 359–ix
    23.    

Haberdar olduğunuz bir advers ilaç reaksiyonunu bildirmek isterseniz lütfen farmakolojilans yasalarının belirlediği gereklilikler uyarınca Sağlık Makamınıza bildirin.